Skip to content

The impact of immersive virtual reality meditation for depression and anxiety among inpatients with major depressive and generalized anxiety disorders.

Jungjoo Lee, Junhyoung Kim, Marcia G Ory

Frontiers in Psychology 2024 DOI: 10.3389/fpsyg.2024.1471269 (opens in new tab)

Read Full Text
Relevant Not relevant

Study at a glance

AI-extracted from the abstract
Characteristics Longitudinal single-arm clinical trial Peer reviewed
Sample size 26
Population Adults with Major Depressive Disorder and Generalized Anxiety Disorder at a community hospital behavioral health unit
Intervention Immersive Virtual Reality Meditation
Duration 10-week intervention, three times per week
Topics Anxiety Depression Meditation
Keywords Heartmath Emotional regulation Mental health Pilot study Virtual reality meditation
Citations 23
Key findings Higher Coherence Achievement Scores after IVRM participation were associated with reductions in depression and anxiety.

Abstract

Mindfulness-Based Cognitive Therapy (MBCT) is a non-pharmacological approach to alleviating depression and anxiety. While technology based MBCT is a standardized cost-effective approach, there have been concerns about its feasibility and effectiveness in clinical settings. The purpose of this study was to investigate the longitudinal relationship between improved emotional regulation resulting from participation in Immersive Virtual Reality Meditation (IVRM) and Major Depressive Disorder (MDD) and Generalized Anxiety Disorder (GAD) as monitored by electrocardiogram. This study was a longitudinal single-arm clinical trial in which the intervention was conducted three times a week for 10 weeks at a behavioral health unit in a community hospital (n = 26). We measured Coherence Achievement Score (CAS), depression, and anxiety. The relationships between CAS, anxiety, depression, and covariates were analyzed using a Generalized Estimated Equation (GEE). The findings of our study provide evidence that the CAS scores indicative of emotional regulation function after IVRM participation were associated with a reduction in depression and anxiety. Among the many technology-based complementary health care interventions that are available to reduce depression and anxiety, IVRM program use increases emotional regulatory function and decrease depression and anxiety.

Comparable studies

Other non-randomized and open-label trials on anxiety, most cited first.

Study Year Design Participants
Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression Patients with treatment-resistant depression 2018 Clinical trial n = 20
Safety, Tolerability, and Efficacy of Psilocybin in 9 Patients With Obsessive-Compulsive Disorder Subjects with obsessive-compulsive disorder (OCD) 2006 Controlled clinical trial
Rapid Resolution of Suicidal Ideation After a Single Infusion of anN-Methyl-D-Aspartate Antagonist in Patients With Treatment-Resistant Major Depressive Disorder Subjects with DSM-IV-diagnosed treatment-resistant major depressive disorder 2010 Open-label trial n = 33
Emotions and brain function are altered up to one month after a single high dose of psilocybin. Healthy volunteers (7 female, 5 male) 2020 Open-label pilot study n = 12
Psilocybin-assisted group therapy for demoralized older long-term AIDS survivor men: An open-label safety and feasibility pilot study Older long-term AIDS survivor (OLTAS) self-identified gay men with moderate-to-severe... 2020 Open-label study

Citations in the library

Cited by 4

Cites 8

and 3 more in the library

Related reading

Explore topics

Anxiety Depression Meditation